EP Patent

EP1855677B1 — 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Assigned to Cambridge Laboratories Ireland Ltd · Expires 2008-12-03 · 17y expired

What this patent protects

The invention provides the use of 3, 11b- cis -dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis or treatment of schizophrenia and other psychoses.

USPTO Abstract

The invention provides the use of 3, 11b- cis -dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prophylaxis or treatment of schizophrenia and other psychoses.

Drugs covered by this patent

Patent Metadata

Patent number
EP1855677B1
Jurisdiction
EP
Classification
—
Expires
2008-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Cambridge Laboratories Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.